NovaBay Pharmaceuticals Reports Record Avenova Sales Day
14 Julho 2023 - 9:30AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality eyecare, skincare and
wound care products, announces that sales of Avenova®-branded
products reached a new record during the Amazon Prime Day event
held July 11-12, 2023, with sales increasing 22% over Prime Day
2022 and 43% over Prime Day 2021.
“Sales of Avenova products during Prime Day 2023 were at an
all-time high since we created our direct-to-consumer sales channel
in 2019. Unit sales and revenue broke daily records, eclipsing all
previous milestones,” said Justin Hall, NovaBay CEO. “We are
encouraged by this growth in our most important sales channel, and
appreciate the loyalty of current Avenova users. We are excited to
attract those new to the brand, many of whom we anticipate will
become long-term customers.
“The results of this year’s Prime Day event further confirms
that our marketing strategies are effectively cutting through the
clutter of products and advertising, and that our core product,
Avenova Antimicrobial Lid and Lash Spray, is used by a broadening
and loyal customer base that values its superior efficacy,” he
added.
NovaBay offers a full line of best-in-class Avenova-branded
products for the management of chronic dry eye. Its flagship
product Avenova Spray is the No. 1 doctor-recommended antimicrobial
lid and lash cleanser. Additional Avenova products include
lubricating eye drops for instant relief, a warm eye compress to
soothe, an antioxidant-rich dietary supplement with omega-3 oils
and the i-Chek to monitor physical eyelid health. All Avenova
products are highly rated on Amazon.com, with Avenova Spray
receiving 4.5 out of 5 stars from nearly 13,000 reviews, including
86% of ratings at 4 stars or above.
NovaBay encourages visitors to the Amazon website to review the
many positive and heartfelt comments from users such as the
following:
- 5 out of 5 stars - Excellent product for dry eye or
meibomian glands Dysfunction! Arrived on time in good condition.
This is the best eyelid cleanser for dry eyes on the market! I use
it twice a day, sometimes three times. Optometrist and
ophthalmologist recommended it to me. Makes my eyes clearer and
eyes feel more comfortable.
- 5 out of 5 stars - Game changer for me! I've
suffered with "goopy eye" for years, particularly in the morning,
waking to crusty lids and/or film on my eyes. I also wear soft
contact lenses (two-week disposables) and they would get very tough
spots on them, clouding my vision. My optometrist said it was
protein deposits, but no amount of cleaning or overnight protein
removal fixed the problem. I purchased Avenova on a whim, and it's
been a total game-changer: within a few days I began waking up with
clear eyes and could wear my contact lenses all day without
discomfort or blurriness. I spray on both eyes at night before bed,
and again in the morning before putting in my lenses. I'm delighted
with the results! Thank you, Avenova!
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
eyecare consumers through online distribution channels such as
Amazon. DERMAdoctor® offers more than 30 dermatologist-developed
skincare products through the DERMAdoctor website, well-known
traditional and digital beauty retailers, and international
distributors. NovaBay also manufactures and sells effective, yet
gentle and non-irritating wound care products. The PhaseOne® brand
is distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our
anticipated sales on Prime Day, marketing strategies, current
partnerships, and any future revenue that may result from such
partnerships and related marketing strategies, as well as generally
the Company’s expected future financial results. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results or achievements to be materially
different and adverse from those expressed in or implied by the
forward-looking statements. Factors that might cause or contribute
to such differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230714384475/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024